X

Kilitch Drugs (India) Ltd. Stock Analysis

Small Cap
Evaluated by 368 users | BSE: 524500 | NSE: KILITCH |
Pharmaceuticals & Drugs
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed 12.76%10.19%12.18%2.92%-1.78%-0.1%-1.86%0.37%4.14%9.2%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 14314610733.214.9192128.150.596.4
Y-o-Y Gr. Rt.-2.4%-26.8%-69%-55.1%27.7%10.5%33.9%79.3%91.1%
Adjusted EPS (Rs.) 8.147.9110.52.64-1.62-0.12-1.70.253.588.46
Y-o-Y Gr. Rt.--2.8%32.7%-74.9%-161.4%NANANA1332%136.3%
Book Value per Share (Rs.) 55.2762.4186.4577.4689.8289.6388.0888.9192.8297.66
Adjusted Net Profit 10.710.513.93.5-2.2-0.2-2.30.34.913
Net Op. Cash Flow (Rs. Cr.) 12.225.5-29.41.5-31.1-7.6180.6-1.37.4
Debt to Cash Flow from Ops 3.532.08-0.30000.011.07-0.631.26
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Kilitch Drugs (India) Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -4.3%45.3%66.2%91.1%
Adjusted EPS 0.4%NANA136.3%
Book Value per Share 6.51.73.55.2
Share Price 1.9% 20.1% 9.5% -34.1%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 15.3713.0913.872.98-1.8-0.13-1.890.283.939.21
Operating Profit Margin (%) 16.7615.1613.26-11.07-25.2-5.99-14.980.4711.0717.02
Net Profit Margin (%) 7.537.171310.53-14.42-0.82-10.721.189.7513.48
Debt to Equity 0.590.640.0800000.010.010.06
Working Capital Days 192148124184632725536280193173
Cash Conversion Cycle 9411193821171702441638664
Entity Percentage Holding
Promoters 68.70%
Non-Institutions 31.30%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Kilitch Drugs(India)'s performance infers:

Kilitch Drugs(India) earnings have grown by 0%, whereas share price has appreciated 20.1% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Kilitch Drugs(India) share prices over the last 10 years. Here is what we found out:

Kilitch Drugs(India) share price has appreciated -4.1% annually over the past ten years.

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India.

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback